Supplementary Figure S3: EMMPRIN on T-EV.

A, Characterization of T-MV and T-Exo preparations by Western Blotting. B, T-MV and T-Exo
were loaded separately onto sucrose gradients and the obtained eight fractions were subsequently analyzed by Western Blotting for the established vesicle markers. The whole cell lysate (=C) is shown as comparative control. C, Microinvasion assay of SK-BR-3 cells stimulated with T-MV S
(1 µg/ml) from SK-BR-3 EMMPRIN knockdown (shEMP) or non-sense control (ns ctl) cells (mean±SD, n=3, *p<0.05). D+E, Uptake of EMMPRIN-negative MV into breast cancer cells:
MCF-7 (D) and SK-BR-3 (E) cells were stimulated for 24 h with PKH26-labeled T-MV S shEMP
or ns ctl (5 µg/ml) and uptake was assessed by fluorescence microscopy (magnification: 10 ×, inserts: bright fields).
Supplementary Figure S4: EMMPRIN and MUC1 expression on breast cancer patientderived MV.
A, MV were isolated from breast cancer patients with metastatic disease by differential ultracentrifugation and analyzed by flow cytometry. Histograms represent the EMMPRIN expression on MV (green) from three breast cancer patients and corresponding tumor-free controls. The respective isotype controls are shown in grey. B, The expression of the tumor marker MUC1 on T-MV was analyzed by flow cytometry. Green: T-MV M , grey: isotype control. C, Additionally, MUC1 expression was determined on patient-derived MV by Western Blotting.
Supplementary Figure S5: LC-MS/MS analysis of IG-and HG-EMMPRIN.
A, Sequence coverage of the EMMPRIN protein in LC-MS/MS analyses. For all four known isoforms of EMMPRIN (1-4), the identified peptides are indicated in yellow. The signal peptide (1-21) or peptides containing the transmembrane domain (324-344) were not found in any sample. B-D, Shown are the parent ion masses (B+C) as well as the MS/MS spectra (D) from the peptides carrying the deamidated N160 or N268 residue which have been recorded on the Orbitrap Velos mass spectrometer in the IG-or HG-EMMPRIN sample. E, LC-MS/MS analysis of the HG-EMMPRIN spot +/-PNGaseF. The HG-EMMPRIN (HG) spot was excised from a 1D-gel and analyzed with or without in-gel deglycosylation by PNGaseF. Deglycosylation allows the detection of both peptides (yellow) carrying the two deamidated N-glycosylation sites N160 and N268 (green) which had been absent, and thus glycosylated, in undigested HG-EMMPRIN. 
Supplementary
LC-MS/MS measurements
Reverse phase separation of tryptic peptides before mass spectrometric analyses was performed on a Proxeon Easy nano-LC system with a binary buffer system consisting of 0.1% acetic acid, 2% acetonitrile in water (buffer A) and 0.1% acetic acid in 100% acetonitrile (buffer B). Peptide separation was achieved using a linear gradient of buffer B from 5 up to 25% within 35 min. MS data were generated using the Orbitrap Velos MS equipped with a nanoelectrospray ion source (PicoTip Emitter, New Objective). After a first survey scan (r = 60,000) MS/MS data were recorded for the 20 highest mass peaks in the linear ion trap at a collision-induced energy of 30%. The exclusion time to reject masses was set to 60 s and the minimal ion signal for MS/MS was 2000. For increasing sequence coverage of EMMPRIN and confirmation of deglycosylated peptides (asparagine deamidation) a second LC-MS/MS analysis was performed using an inclusion list for modified and unmodified parent ion masses (see Supplementary Figures S5B and C) .
Mass spectrometry data analysis
Proteins were initially identified by searching against a forward-reverse Swiss-Prot database limited to human entries (v2013-11, n = 38,520, including common contamination sequences) using the SEQUEST algorithm v3.5 (Sorcerer v4.04, Sage-N Research Inc). Search parameters were 10 p.p.m. parent mass tolerance and 0.6 Da for fragment ion mass tolerance.
Propionamide modification of cysteins, methionine oxidation and asparagine deamidation were specified as variable modifications. Peptides were annotated on a false positive rate of 0.6% calculated by the Peptide Prophet algorithm. For protein assembling and grouping
Trans-Proteomic Pipeline (v4.4.0, Protein Prophet) was used, whereas only proteins with at least two significant peptides were considered for identification and Sequest identifications required at least XCorr scores of greater than 2.5 for double and 3.0 for triple charged ion.
Additionally, Scaffold (version Scaffold_4.1.1, Proteome Software Inc) was used to validate MS/MS based peptide and protein identifications. Peptide identifications were accepted if they could be established at greater than 95.0% probability by the Peptide Prophet algorithm (Keller et al., 2002) with Scaffold delta-mass correction. Protein identifications were accepted if they could be established at greater than 95.0% probability and contained at least 2 identified peptides. Protein probabilities were assigned by the Protein Prophet algorithm (Nesvizhskii et al., 2003) . Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. For detection of the specific glycosylation sites of EMMPRIN an artificial database was used for SEQUEST analysis, whereas all search and annotation parameters were used as described above. The database was build including an additional EMMPRIN-2 isoform without the signal peptide sequence (1-21). The unique T-MV proteins identified by LC-MS/MS (dataset available at www.evpedia.info (Choi et al., 2013; Kim et al., 2013; Choi et al., 2014)) were analyzed using Ingenuity Pathway Analysis (Ingenuity ® Systems, www.ingenuity.com) to identify potential upstream regulators, canonical pathways and molecular functions. Statistical significance was calculated by Fisher's exact test.
Peptide synthesis and purification
Sequences for the synthetic EMMPRIN blocking peptides are SLNDSATEVTGHRWLK (P-N160) and ALMNGSESRFFVSSS (P-N268) and have been previously published (Sato et al., 2009 ). For each peptide a random control peptide was created by shuffling the amino acid sequence resulting in LSDSNGTEAHVTLRWK (P-N160rd) and VFSMELRSNSGFSAS (PN268rd). Peptides were synthesized using Fmoc solid phase peptide synthesis on a Rink amide MBHA resin (loading density 0.57 mmol/g). For the attachment of the first amino acid the resin was placed in a syringe equipped with a polyethylene-frit (BD) and swollen in DMF for 2 h. For loading the resin, the Fmoc-amino acid (5.0 eq. relative to the resin loading), HOBt (5.0 eq.) and DIC (10 eq.) were dissolved in a minimum of DMF, transferred to the resin and allowed to react using Discover microwave reaction cavity (CEM, 40 °C, 20 W, 10 min). Subsequently, the reaction mixture was filtered and the resin was thoroughly washed with DMF. The loading procedure was repeated twice. Finally, the resin was washed with DMF, NMP and DCM and dried under reduced pressure over night. The resin loading was estimated via UV analysis of the dibenzofulven concentration resulting from Fmocdeprotection. Therefore, the particular resin (5 mg) was placed in a graduated flask (10 ml) and 2% DBU in NMP was added. After gentle shaking for 1 h, the reaction mixture was diluted with acetonitrile up to 10 ml. The solution was further diluted with acetonitrile (1/12.5) and transferred to a UV cell. The absorption of the cleaved Fmoc species was detected at 304 nm. When the loading density of the resin was considered to be sufficient, the remaining free amino functionalities were acetylated using acetic acid anhydride (1.0 eq.), DIPEA (0.3 eq.), HOBt (0.03 eq.) in NMP (20 eq.) (2 × 10 min). The four peptides were automatically synthesized via SPPS-protocol on a 0.1 mmol scale using the Liberty peptide synthesizer equipped with a Discover microwave reaction cavity (CEM). The Fmoc-protecting group was removed by treatment with 0.1 M HOBt in piperidine/NMP (1/4, v/v) . In each coupling an amino acid building block was used in an excess of five equivalents (0.2 M in NMP) and activated with HBTU (4.9 eq.) and HOBt (5.0 eq.) in NMP (0.5 M). As activator base DIPEA
